Clinical trials: Cancer, Head
Advanced Solid Tumor
HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors
HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT06112704
- Testing
- HS-20093
- Where
- 21 sites in China
- Volunteers
- 220 people
- Sponsor
- Hansoh BioMedical R&D Company
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
Study of CHS-114 in Participants With Advanced Solid Tumors
This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.
- Trial name
- NCT05635643
- Testing
- CHS-114, toripalimab
- Where
- 12 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Coherus Oncology, Inc.
Esophageal Neoplasm, Adenocarcinoma of the Gastroesophageal Junction
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
An Expanded Access Protocol for use of DKN-01 for the treatment of advanced solid tumors.
- Conditions
- Esophageal Neoplasm, Adenocarcinoma of the Gastroesophageal Junction, GastroEsophageal Cancer, Squamous Cell Carcinoma
- Trial name
- NCT04681248
- Testing
- DKN-01
- Where
- 5 sites in United States
- Sponsor
- Leap Therapeutics, Inc.
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Barrett Esophagus, Esophageal Cancer
Clinical Utility of Methylation-based Prognostic Assay for Barrett's Esophagus
Capsulomics has developed a prognostic assay for patients with diagnosed Barrett's esophagus (BE). This study will measure how gastroenterologists make surveillance and treatment management decisions when presented with different…
- Trial name
- NCT05846971
- Testing
- Educational materials on validated methylation assay
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Capsulomics, Inc.
Advanced or Metastatic Solid Tumors, Breast Cancer
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT05787587
- Testing
- IDE-161, Pembrolizumab
- Where
- 27 sites in United States
- Volunteers
- 216 people
- Sponsor
- IDEAYA Biosciences
Metastatic Sarcoma, Esophageal Cancer
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to…
- Conditions
- Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- PHANTOM (NCT06298916)
- Testing
- 64Cu-LNTH-1363S
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Lantheus Medical Imaging
Triple Negative Breast Cancer, Head & Neck Cancer
PCA062 in pCAD-positive Tumors.
A first-in-human sttudy using PCA062 in patients with p-CAD positive solid tumors.
- Conditions
- Triple Negative Breast Cancer, Head & Neck Cancer, Esophageal Cancer
- Trial name
- NCT02375958
- Testing
- PCA062
- Where
- 7 sites in United States, France and 4 more
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Esophageal Squamous Cell Carcinoma
A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom
This purpose of this observational study is to review medical chart and patient survey data collection within an early access to medicines scheme (EAMS) program.
- Trial name
- NCT04936399
- Testing
- Nivolumab
- Where
- 36 sites in United Kingdom
- Volunteers
- 87 people
- Sponsor
- Bristol-Myers Squibb
Nasopharyngeal Carcinoma
A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)
A phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic nasopharyngeal carcinoma who had failed at least two lines of platinum-based…
- Trial name
- NCT06118333
- Testing
- BL-B01D1, capecitabine, gemcitabine
- Where
- China
- Volunteers
- 386 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Cancer of Head and Neck
Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer
The purpose of this study is to determine the safety and tolerability of GL-ONC1 administered intravenously in combination with radiation therapy and cisplatin (CDDP)in patients with locoregionally advanced head and neck cancer.
- Trial name
- NCT01584284
- Testing
- GL-ONC1
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Genelux Corporation
Treatment of Venous Thromboembolism in Cancer Patients, Venous Thromboembolism
An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism)
This is an observational study in which patient data from the past on venous thromboembolism (VTE) in people with cancer is studied. In observational studies, only observations are made without specified advice or interventions.
- Conditions
- Treatment of Venous Thromboembolism in Cancer Patients, Venous Thromboembolism, Cancer
- Trial name
- H2H-OSCAR-US (NCT05461807)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban
- Where
- Germany
- Volunteers
- 2,437 people
- Sponsor
- Bayer
Advanced Solid Tumors
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.
- Trial name
- NCT03861793
- Testing
- ALKS 4230, Pembrolizumab
- Where
- 48 sites in United States, Canada and 4 more
- Volunteers
- 116 people
- Sponsor
- Mural Oncology, Inc
Candidiasis, Oral, Thrush
Novel Rinse to Treat in Oral Candidiasis in Cancer Patients
The purpose of the study is to evaluate the efficacy of Iocide oral rinse as a treatment for Oral Candidiasis in any patient including but not limited to patients receiving radiation therapy or who have previously received…
- Conditions
- Candidiasis, Oral, Thrush, Candidiasis
- Trial name
- NCT00612963
- Testing
- Frio Oral Rinse
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Biomedical Development Corporation
Advanced Solid Tumors, Gastric Cancer
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
The purpose of this study is to assess the safety and effects of PF-07265028 as monotherapy and in combination with sasanlimab. The study aims to identify the maximum tolerated dose (MTD) of PF-07265028 as monotherapy; evaluate…
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer, Urothelial Cancer
- Trial name
- NCT05233436
- Testing
- PF-07265028, Sasanlimab
- Where
- 8 sites in United States, Japan
- Volunteers
- 21 people
- Sponsor
- Pfizer
Thyroid Nodule
Percutaneous Laser Ablation in Benign Thyroid Nodules.Long Term Results
Thyroid nodule pathologies occur frequently and represent a clinical issue for the endocrinologists, surgeons, nuclear physicians as well as the general practitioners.
- Trial name
- NCT00858104
- Testing
- Percutaneous Laser Ablation
- Where
- 4 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Elesta S.R.L.
Nonsmall Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy
A Post-marketing Surveillance Study to Evaluate the Effectiveness and Safety of Docetaxel-Based Chemotherapy
- Trial name
- NCT02972216
- Testing
- Nolbaxol, Taxotere, cisplatin
- Volunteers
- 40 people
- Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
Stomach Neoplasms, Esophageal Neoplasms
A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer
The purpose of this study is to investigate the activity of amivantamab in gastric cancer (GC) and esophageal cancer (EC) participants (Phase 2a), and to characterize the preliminary antitumor activity of amivantamab in selected…
- Trial name
- NCT04945733
- Testing
- Amivantamab
- Where
- 10 sites in Japan
- Volunteers
- 62 people
- Sponsor
- Janssen Pharmaceutical K.K.
Esophageal Squamous Cell Carcinoma
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus.
- Trial name
- NCT06780111
- Testing
- Pembrolizumab, I-DXd, Leucovorin
- Where
- 52 sites in United States, Brazil and 14 more
- Volunteers
- 298 people
- Sponsor
- Merck Sharp & Dohme LLC
Seborrheic Keratosis
Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis
This study is primarily designed to investigate whether treatment, once daily for up to three consecutive days, with PEP005 (ingenol mebutate) Gel, 0.05% will be safe and tolerable in patients with Seborrhoeic Keratosis on…
- Trial name
- NCT01214564
- Testing
- PEP005 (ingenol mebutate) Gel
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Peplin